IVim Technology

IVim Technology FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of IVim Technology (460470.KQ) as of Nov 3, 2026 is 176.90 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 189.70 % — a change of -6.75% (lower).

FCF Conversion

176.90 %

YoY

-6.75%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of IVim Technology is 2025 176.90 % . FCF Conversion Rate (FCF/EBITDA) of IVim Technology was 2024 189.70 % . It decreases by -6.75% lower compared to the previous year.

The IVim Technology FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2021
187.87 KRW
Jan 1, 2022
46.27 KRW
Jan 1, 2023
78.16 KRW
Jan 1, 2024
189.70 KRW
Jan 1, 2025
176.90 KRW
The IVim Technology FCF Conversion history
YEARFCF ConversionYoY
176.90 %-6.75%
189.70 %+142.69%
78.16 %+68.92%
46.27 %-75.37%
187.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IVim Technology Stock analysis

What does IVim Technology do? IVim Technology Inc generates revenue through the development, manufacture, and sale of biological microscopes utilizing in vivo live cell imaging platform technology. The company offers imaging accessories and provides cellular-level imaging acquisition services inside living bodies along with kinetic analysis services for injected drugs. Its primary customers are healthcare institutions requiring advanced imaging solutions for research and diagnostic purposes. The firm targets the health care equipment and supplies industry segment focused on in vivo cellular analysis and drug development support. The company's core products include biological microscopes capable of analyzing complex dynamic changes in numerous cells in vivo, imaging accessories, and specialized services for cellular imaging and drug kinetics. These offerings are tailored to meet the needs of medical research facilities and pharmaceutical companies seeking to enhance their in vivo analysis capabilities. IVim Technology Inc's business model centers on providing integrated solutions for cellular-level imaging and drug efficacy assessment within the healthcare sector. Revenue streams are derived from direct sales of microscopes and accessories to healthcare providers and research institutions. The company also monetizes its expertise through service-based contracts for cellular imaging acquisition and kinetic drug analysis. These services are particularly valuable for pharmaceutical firms conducting preclinical studies and developing new treatments. The firm's focus on in vivo live cell imaging technology positions it as a key supplier for advanced medical research applications. IVim Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IVim Technology stock

FCF Conversion Rate (FCF/EBITDA) of IVim Technology is 176.90 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of IVim Technology changed from 189.70 % to 176.90 %, representing a -6.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) IVim Technology since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s IVim Technology with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — IVim Technology

All Key Metrics — IVim Technology